2BB score and signals
Avalo Therapeutics, Inc.’s current 2BB score is 37 out of 100, built from the signal categories below.
| Signal | Score | Reading |
|---|
| Activity | 53 | Moderate |
| Momentum | 45 | Stable |
| Financial strength | 31 | Weak |
| Quality | 60 | Strong |
| Risk | 48 | Moderate |
Company facts
| Headquarters | Rockville, Pennsylvania, United States |
| Founded | 2011 |
| Employees | 33 |
| 52-week range | $8.41 – $24.27 |
Recent earnings
| Report date | EPS actual | EPS estimate | Revenue actual | Revenue estimate |
|---|
| 2026-11-04 | — | -0.5912 | — | $0.00 |
| 2026-08-05 | — | -0.5935 | — | $0.00 |
| 2026-05-13 | -0.98 | -1.0461 | $0.00 | $0.00 |
| 2026-03-23 | -1.13 | -1.4933 | $0.00 | $0.00 |
Related companies
